Literature DB >> 16484652

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population.

A Czaplinski1, A A Yen, S H Appel.   

Abstract

In a large cohort of 1034 patients with the diagnosis of definite or probable amyotrophic lateral sclerosis (ALS), the association of forced vital capacity (FVC) at baseline with (a) time to progression of 20 points in Appel ALS (AALS) score or (b) tracheostomy free survival was investigated. The median survival of ALS patients with baseline FVC <75% was 2.91 years, compared with 4.08 years for patients with baseline FVC >75% (p<0.001). Patients with baseline FVC <75% progressed more rapidly (taking 8.0 months to progress 20 AALS points) compared with patients with baseline FVC >75% (10.0 months, p<0.001). Moreover, FVC at first examination was identified as a significant predictor of survival and disease progression in both univariate and multivariate Cox regression models, after adjustment for age, sex, site of onset, diagnostic delay, riluzole therapy, and use of bilateral positive airway pressure and percutaneous endoscopic gastrostomy (p<0.001). We conclude that a single FVC value obtained at an initial visit may serve as a clinically meaningful predictor of survival and disease progression in ALS.

Entities:  

Mesh:

Year:  2006        PMID: 16484652      PMCID: PMC2077717          DOI: 10.1136/jnnp.2005.072660

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  23 in total

Review 1.  Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research.

Authors:  R G Miller; T L Munsat; M Swash; B R Brooks
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

2.  Design using historical controls.

Authors:  Albert Yen; Ericka Simpson; Lanny Haverkamp; Stanley Appel
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2004-09

3.  Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis.

Authors:  P C Gay; P R Westbrook; J R Daube; W J Litchy; A J Windebank; R Iverson
Journal:  Mayo Clin Proc       Date:  1991-07       Impact factor: 7.616

4.  A rating scale for amyotrophic lateral sclerosis: description and preliminary experience.

Authors:  V Appel; S S Stewart; G Smith; S H Appel
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

5.  Disease progression in amyotrophic lateral sclerosis: predictors of survival.

Authors:  T Magnus; M Beck; R Giess; I Puls; M Naumann; K V Toyka
Journal:  Muscle Nerve       Date:  2002-05       Impact factor: 3.217

6.  A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients.

Authors:  C E Jackson; J Rosenfeld; D H Moore; W W Bryan; R J Barohn; M Wrench; D Myers; L Heberlin; R King; J Smith; D Gelinas; R G Miller
Journal:  J Neurol Sci       Date:  2001-10-15       Impact factor: 3.181

7.  The ALSFRSr predicts survival time in an ALS clinic population.

Authors:  P Kaufmann; G Levy; J L P Thompson; M L Delbene; V Battista; P H Gordon; L P Rowland; B Levin; H Mitsumoto
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

8.  A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.

Authors:  M E Cudkowicz; J M Shefner; D A Schoenfeld; R H Brown; H Johnson; M Qureshi; M Jacobs; J D Rothstein; S H Appel; R M Pascuzzi; T D Heiman-Patterson; P D Donofrio; W S David; J A Russell; R Tandan; E P Pioro; K J Felice; J Rosenfeld; R N Mandler; G M Sachs; W G Bradley; E M Raynor; G D Baquis; J M Belsh; S Novella; J Goldstein; J Hulihan
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

9.  Early symptom progression rate is related to ALS outcome: a prospective population-based study.

Authors:  A Chiò; G Mora; M Leone; L Mazzini; D Cocito; M T Giordana; E Bottacchi; R Mutani
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

10.  Amyotrophic lateral sclerosis. Its natural history.

Authors:  J T Caroscio; M N Mulvihill; R Sterling; B Abrams
Journal:  Neurol Clin       Date:  1987-02       Impact factor: 3.806

View more
  50 in total

1.  Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline.

Authors:  Douglas A McKim; Jeremy Road; Monica Avendano; Steve Abdool; Fabien Cote; Nigel Duguid; Janet Fraser; Fracois Maltais; Debra L Morrison; Colleen O'Connell; Basil J Petrof; Karen Rimmer; Robert Skomro
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

2.  Prognosis of amyotrophic lateral sclerosis with respiratory onset.

Authors:  Christen L Shoesmith; Karen Findlater; Ann Rowe; Michael J Strong
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-06       Impact factor: 10.154

3.  Amyotrophic lateral sclerosis: clinical management and research update.

Authors:  Jinsy Andrews
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 4.  Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Authors:  Carlayne E Jackson; April L McVey; Stacy Rudnicki; Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

5.  MISSING DATA IMPUTATION IN THE ELECTRONIC HEALTH RECORD USING DEEPLY LEARNED AUTOENCODERS.

Authors:  Brett K Beaulieu-Jones; Jason H Moore
Journal:  Pac Symp Biocomput       Date:  2017

6.  Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.

Authors:  Radhika Raheja; Keren Regev; Brian C Healy; Maria Antonietta Mazzola; Vanessa Beynon; Felipe Von Glehn; Anu Paul; Camilo Diaz-Cruz; Taha Gholipour; Bonnie I Glanz; Pia Kivisakk; Tanuja Chitnis; Howard L Weiner; James D Berry; Roopali Gandhi
Journal:  Muscle Nerve       Date:  2018-03-25       Impact factor: 3.217

7.  Respiratory and nutritional support in amyotrophic lateral sclerosis.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2014-02       Impact factor: 3.598

8.  Changes in tongue pressure, pulmonary function, and salivary flow in patients with amyotrophic lateral sclerosis.

Authors:  Caryn Easterling; Jodi Antinoja; Susan Cashin; Paul E Barkhaus
Journal:  Dysphagia       Date:  2012-12-15       Impact factor: 3.438

Review 9.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

10.  Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency.

Authors:  Pierluigi Carratù; Lucia Spicuzza; Anna Cassano; Mauro Maniscalco; Felice Gadaleta; Donato Lacedonia; Cristina Scoditti; Ester Boniello; Giuseppe Di Maria; Onofrio Resta
Journal:  Orphanet J Rare Dis       Date:  2009-03-10       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.